#TaroPharma Q4 revenue up 5.3% $146.6 Million Vs $139.2 Million (QoQ)

CNBC-TV18 Alert: Taro Pharma is a subsidiary of Sun Pharma

#TaroPharma board has appointed an independent committee order to evaluate this proposal, proposed purchase price is at a premium of 31.2% over Taro's closing price on May 25, 2023

#SunPharma subsidiary #TaroPharma reported a 12.5% jump in its overall sales for the January-March quarter to $164.9 million, writes @ekta_batra

▶️Gross profit up 16% at $87.4 million vs $75.7 million (YoY)
▶️Operating income down 5% at $8.8 million vs $9.3 million (YoY)
▶️Net income at $15.1 million vs $6.9 million (YoY)